{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-031878","form_type":"8-K","ticker":"OCEA","cik":"0001869974","company_name":"Ocean Biomedical, Inc.","filed_at":"2023-09-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.939043+00:00","generated_at":"2026-06-10T23:38:34.865900+00:00","sec_items":["5.07","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"confidence":"high","headline":"Stockholders approve Nasdaq Proposal for share issuance from convertible notes and warrant","bullets":["Special meeting held Aug 30, 2023; 25,756,950 shares present (~75.6% of 34,062,724 outstanding).","Vote: 25,268,869 for, 472,508 against, 15,573 abstain on the Nasdaq Proposal.","Proposal allows potential conversion of up to three Senior Secured Convertible Notes and warrant under May 15 SPA.","Only one $7.56M note issued to date; ~24,400 shares issued for accrued interest; no warrant exercised.","Full conversion of current note would equal ~2% of outstanding common stock."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-031878","json":"https://secwatch.observer/filing/0001493152-23-031878.json","markdown":"https://secwatch.observer/filing/0001493152-23-031878.md","text":"https://secwatch.observer/filing/0001493152-23-031878.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1869974/000149315223031878/0001493152-23-031878-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1869974/000149315223031878/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T23:38:34.865900+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"28cd89338e76fc53d6cff35c57fd84034ef13856","claim":"Ocean Biomedical, Inc. shareholders approved Potential issuance of shares upon conversion of Senior Secured Convertible Notes and exercise of warrant under Nasdaq Listing Rule 5635(d) at the 2023-08-30 meeting.","evidence_excerpt":"On August 30, 2023, Ocean Biomedical, Inc. (the “Company”) held a special meeting of stockholders (the “Meeting”). As of the close of business on August 3, 2023, the record date for the Meeting, there were 34,062,724 shares of the Company’s common stock issued and outstanding. A total of 25,756,950 shares were present or represented by proxy at the Meeting, representing approximately 75.6% of the issued and outstanding shares of common stock of the Company as of the record date for the Meeting, which constituted a quorum to conduct business. As more fully described in the Company’s definitive proxy statement filed with the U.S. Securities and Exchange Commission (the “SEC”) on August 4, 2023 (the “Proxy Statement”), the primary purpose of the Meeting was to submit to the Company’s stockholders a proposal to consider and approve, for purposes of complying with Nasdaq Listing Rule 5635(d) (the “Nasdaq Proposal”), the potential issuance of shares of Company common stock that may later be","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1869974/000149315223031878/0001493152-23-031878-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-08-30"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}